The 7th Joint Session between JDDW-KDDW-TDDW4(JDDW)
Thu. November 2nd   14:00 - 17:00   Room 10: Portopia Hotel Waraku
JKT4-3
 Proton Therapy for Hepatocellular Carcinoma
Bing-Shen Huang
Department of Radiation Oncology, Chang Gung Memorial Hospital
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Most HCC patients have impaired liver function because of hepatitis or liver cirrhosis, and only approximately 20-40% of patients are candidates for resection. Maximal preservation of normal liver volume and function is an important consideration in the choice of treatment.
Proton beam therapy (PBT) for HCC treatment has been applied for decades, and many clinical results have shown excellent 3-year to 5-year local control (LC) rate ranging from 85-95% and nearly no major complications.
From 2015 to 2023, more than 6000 patients were treated with PBT at Chang-Gung Memorial Hospital. More than a quarter of patients have liver cancers. The PBT was considered in the patients that were not suitable for surgery or radiofrequency (RFA) and discussed in the multidisciplinary conference. The PBT dose were 72.6CGE/22fx and 66CGE/10fx, depending on tumor location. The largest tumor diameter was more than 5 cm, and more than 30% of tumors are larger than 10 cm in diameter. More than 40% were major tumor vascular invasion. The in-field control rate was was more than 90%.
According to previous clinical results and our experiences, PBT can be a good alternative treatment for patients unsuitable for surgery.
Page Top